Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : V-Sars
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Immunitor
Deal Size : Inapplicable
Deal Type : Inapplicable
Tableted COVID-19 Therapeutic Vaccine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : V-Sars
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Immunitor
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : V8
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunotherapy of Chronic Kidney Failure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : V8
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunitor publishes interim results from Phase III trial
Details : The trial is continuation of successful 75-patient Phase II trial published in 2017 in the Journal of Hepatocellular Carcinoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 02, 2020
V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 16, 2019
Open Label Immunotherapy Trial for Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 28, 2018
Open Label Immunotherapy Trial for Ovarian Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 14, 2018
Lead Product(s) : V3-Myoma
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Immunotherapy of Myoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 08, 2018
Lead Product(s) : V3-Myoma
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunotherapy of Cervical Cancer With V3-Cervix
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 08, 2018
Lead Product(s) : V-Endo
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Ekomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Immunotherapy of Endometriosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 13, 2017
Lead Product(s) : V-Endo
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Ekomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : V3-P
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 24, 2017
Lead Product(s) : V3-P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable